The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers

Piotr Pierzyński; Oliver Pohl; Line Marchand;  Shari Mackens;  Ulrike Lorch;  Jean-Pierre Gotteland; Christophe Blockeel 

RBMO. Vol. 43, Issue 2, p184-192, August 01, 2021.

Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials

G Griesinger, C Blockeel, P Pierzynski, H Tournaye, H Višňová, A Humberstone, P Terrill, O Pohl, E Garner, J Donnez, E Loumaye
Human Reproduction, Volume 36, Issue 4, April 2021, Pages 1007–1020

Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers

Jörg Täubel, Ulrike Lorch, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Dilshat Djumanov, Georg Ferber, Line Marchand, Jean-Pierre Gotteland & Oliver Pohl

Scientific Reports 11, Article number: 6404 (2021)

The use of nolasiban, a novel oxytocin receptor antagonist, prior to embryo transfer: does it help?

Ernest Loumaye, MD, PhD

19th World Congress of Gynecological Endocrinology (On Line Congress 2-5 December 2020, available until 15 April 2021)

Abstract on p. 39 – part of SYMP19: Recent development in IVF

Gynecological and Reproductive Endocrinology and Metabolism 2020; Supplement 1 – Book of abstracts

The effect of the oral oxytocin antagonist, nolasiban, on pregnancy rates in women undergoing embryo transfer following IVF

Georg Griesinger, MD, PhD; Jacques Donnez, PhD, MD; Andrew Humberstone, PhD; Paul Terrill, PhD; Oliver Pohl, DVM, MPH, MSc; Elizabeth Garner, MD, MPH; Ernest Loumaye, MD, PhD

ASRM 2020 Virtual Congress, October 2020

Poster session, abstract – Poster P. 482, page e303

Fertility and Sterility, Volume 114, No. 3, Supplement, September 2020, Poster P-482, page e303

The mechanism of action of oxytocin receptor antagonists (OTRan) in ART – a study of nolasiban on biomarkers of uterine receptivity in healthy female volunteers

O. Pohl, L. Marchand, P. Pierzyński, C. Blockeel, S. Mackens, U. Lorch, J.P. Gotteland

ESHRE 36th Virtual Annual Meeting, 5-8 July 2020

Human Reproduction, Volume 35, Issue Supplement_1, July 2020, on pages i83–i84

Babies Born Following Administration of Nolasiban Before Embryo Transfer (ET) After IVF: Neonatal and Infant Development Outcomes From a Double-Blind, Placebo-Controlled, Clinical Trial

Humberstone A., Terrill P., Macgregor L., Loumaye E.

ASRM 2019 Scientific Congress & Expo, 12-16 October 2019, Philadelphia, PA

Fertility and Sterility Vol. 112, No. 3, Supplement, September 2019. Abstract on pages e7-e8.

Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium

Sung Hye Kim, Lucia Riaposova, Hauwa Ahmed, Oliver Pohl, André Chollet, Jean-Pierre Gotteland, Aylin Hanyaloglu, Phillip R. Bennett & Vasso Terzidou

Kim SH, Riaposova L, Ahmed H, et al. Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium. Sci Rep. 2019;9(1):5792. Published 2019 Apr 8. doi:10.1038/s41598-019-42181-2

A Placebo-Controlled, Randomized, Double-Blind, Phase 3 Study Assessing Ongoing Pregnancy Rates After Single Oral Administration of a Novel Oxytocin Receptor Antagonist, Nolasiban, Prior to Single Embryo Transfer

Visnova H., Tournaye H. J., Humberstone A., Terrill P., Macgregor L., Loumaye E.

ASRM 2018, 6-10 October 2018, Denver, CO

Fertility and Sterility September 2018 Volume 110, Issue 4, Supplement, Page e45, Abstract O101

Effects of the oral oxytocin receptor antagonist nolasiban on early embryonic development

O. Pohl, D. Perks, R. Sisti, J.P. Gotteland

ESHRE Annual Conference, 01-04 July 2018, Barcelona, Spain
Abstract P-121 on Pages i196-i197

Abstract P-121 on Pages i196-i197 – Human Reproduction, Volume 33, Issue suppl_1, July 2018, Pages i1–i541,